Monovalent molecules that bind to iga and methods of use
By designing a monovalent antigen-binding molecule and utilizing its binding to IgA and high affinity for FcRn, efficient degradation of serum IgA was achieved, solving the treatment problem of IgA-mediated diseases in existing technologies and providing an effective treatment method.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ARGENX BVBA(BE)
- Filing Date
- 2024-12-20
- Publication Date
- 2026-07-17
AI Technical Summary
The lack of effective drugs in the current technology to regulate and reduce excessive IgA levels in serum makes IgA-mediated diseases difficult to treat.
A monovalent antigen-binding molecule was developed, which contains an antigen-binding domain that binds to IgA and a variant Fc region. This molecule can enhance the affinity for binding to the human neonatal Fc receptor (hFcRn), reduce the affinity for IgA binding at acidic pH, prevent IgA from binding to its receptor, and degrade IgA through an FcRn-mediated internalization pathway.
Monovalent antigen-binding molecules significantly reduce serum IgA levels and improve IgA clearance efficiency, making them more effective than divalent binding molecules and suitable for treating IgA-mediated diseases.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3